TNFSF10 and neoplasm: A PEGylated human recombinant TRAIL named TLY012 ameliorated skin fibrosis, pancreatic disease and cirrhosis in preclinical models [211] and is being actively investigated for anticancer effects in tumor models but is yet to be tested in TNBC models [212].